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PCoronary Artery Disease
CXCL16 Is a Marker of Inflammation,
Atherosclerosis, and Acute Coronary Syndromes in Humans
Michael Lehrke, MD,*§ Segan C. Millington, BS,* Martina Lefterova, BS,*
Reshmaal Gomes Cumaranatunge, MD,† Philippe Szapary, MD, MSCE,†‡
Robert Wilensky, MD, FACC,† Daniel J. Rader, MD,*†‡ Mitchell A. Lazar, MD, PHD,*
Muredach P. Reilly, MB, MSCE*†‡
Philadelphia, Pennsylvania; and Munich, Germany
Objectives This study was designed to determine the association of CXCL16 with inflammation, atherosclerosis, and acute
coronary syndromes.
Background Vascular inflammation coincides with uptake of modified lipoproteins in the pathogenesis of atherosclerosis.
CXCL16 is a protein that shares scavenger receptor function, promoting uptake of modified lipids, with the activ-
ities of an inflammatory chemokine. However, the role of CXCL16 in atherosclerosis remains uncertain.
Methods The effect of inflammatory stimuli on CXCL16 gene and protein expression was studied in macrophages, mice,
and humans, and the association of sol-CXCL16 with risk factors, atherosclerosis, and acute coronary syndromes
was determined in humans.
Results Endotoxin induction of CXCL16 in human macrophages was attenuated by aspirin, nuclear factor (NF)-kappa-B
inhibition and peroxisome proliferator-activated receptor (PPAR)-gamma agonists. Experimental human endotox-
emia (n  6) led to an 8-fold increase in whole-blood CXCL16 messenger ribonucleic acid (p  0.001) and a
1.7-fold increase in soluble (sol)-CXCL16 (p  0.001), a cleaved active chemokine. Rosiglitazone-blocked endo-
toxin induced sol-CXCL16 in mice (p  0.001), and pioglitazone (n  28), compared to placebo (n  28), low-
ered plasma sol-CXCL16 in metabolic syndrome subjects (p  0.05). In a nested case-control study of acute and
chronic coronary artery disease (n  699), sol-CXCL16 levels correlated with inflammatory and metabolic risk
factors and were associated with chronic coronary artery disease (odds ratio [OR] [95% confidence interval],
above vs. below median; 1.60 [1.01 to 2.58]; p  0.04) and acute coronary syndromes (OR 2.52 [1.32 to 4.82],
p  0.005) following adjustment for established risk factors, medications, and C-reactive protein levels.
Conclusions Our findings suggest that CXCL16 may play a pro-inflammatory role in human atherosclerosis, particularly in
acute coronary syndrome. (J Am Coll Cardiol 2007;49:442–9) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.034p
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Wascular inflammation and uptake of modified lipoprotein
onverge in atherosclerosis (1). Accumulation of lipids in
he vascular wall serves as an attractant for invading immu-
ologic cells. Modified lipoproteins are recognized by pat-
ern recognition receptors, termed scavenger receptors, ex-
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January 30, 2007:442–9 CXCL16 in Inflammation and Atherosclerosisied by an inflammatory state that reflects risk of cardio-
ascular disease (CVD) (3).
Recently, a protein called CXCL16 has been identified,
hich combines scavenger receptor functions with the
roperties of an inflammatory chemokine (4). CXCL16, a
ransmembrane protein, is composed of an extracellular
hemokine domain fused to a trans-membrane mucin stalk
4). The chemokine domain acts as an attractant for cells
xpressing the CXCR6 receptor (4,5), but also as a scaven-
er receptor facilitating uptake of oxidized low-density
ipoprotein (ox-LDL), phoshatidylserine, and bacteria (6).
he extracellular part of CXCL16 undergoes cleavage by
he metalloproteinase ADAM 10 creating a soluble chemo-
ine (sol-CXCL16) (4,7), which activates CXCR6-
xpressing T-cells (4,5,7). CXCL16 has been implicated in
ariety of inflammatory diseases such as hepatitis (8) and
ncephalomyelitis (9), but its role in atherosclerosis is
ebated (10,11).
CXCL16 is expressed in macrophages (5) and aortic smooth
uscle cells (12,13), and expression is enriched in atheroscle-
otic plaques (6,14). Pro-inflammatory stimuli increase
XCL16 expression (4,7,13), enhancing uptake of ox-LDL
nd facilitating foam cell formation (14). Furthermore, sol-
XCL16 stimulates vascular cell proliferation, and a prelimi-
ary study found that a polymorphism of the CXCL16 gene
as associated with the severity of coronary artery disease
CAD) (15). Despite this evidence, a recent rodent study
uggests an atheroprotective effect of CXCL16 (11), and
lasma sol-CXCL16 levels were reported to be decreased in
atients with coronary atherosclerosis (10), calling into ques-
ion CXCL16’s role in human atherosclerosis. We describe the
nflammatory regulation of CXCL16 in cells, mice, and hu-
ans and its association with CVD risk factors, stable CAD,
nd acute coronary syndromes (ACS) in humans.
ethods
acrophage studies. Human and mouse macrophages
ere isolated and differentiated as described (16). Experiments,
fter overnight equilibration with serum-free medium (Gibco/
nvitrogen, Carlsbad, California), included treatment as indi-
ated with lipopolysaccharide (LPS) (Sigma, St. Louis, Mis-
ouri), aspirin (Sigma), SN50, and control peptide (Biomol,
lymouth Meeting, Pennsylvania). Human macrophages
ere treated in the presence of 5 ng/ml granulocyte mac-
ophage colony-stimulating factor. Adenoviruses overex-
ression of activated I-kappa-B kinase (gift, Steven Shoel-
on) or control vector was performed as described (16).
ibonucleic acid (RNA) and protein quantification. Ri-
onucleic acid quantification was performed by Taqman real-
ime polymerase chain reaction (16) using primers and probes
Perkin Elmer/Applied Biosystems) for CXCL16, tumor ne-
rosis factor (TNF)-alpha, 18s-RNA, or beta-actin. CXCL16
rotein concentrations in cell media, mouse serum, and human
lasma were assessed with a commercial enzyme-linked im-
unosorbent assay (ELISA) (R&D Systems) and normalized Eo cell protein or per ml plasma (in
ivo studies). Plasma C-reactive
rotein (CRP) (high-sensitivity
urbidimetric immunoassay; Wako
td., Osaka, Japan), resistin,
NF-alpha, and soluble intercel-
ular adhesion molecule (sol-
CAM1) (ELISAs, Linco, St.
ouis, Missouri) were determined
y commercial assays. Intra- and
nterassay coefficients of variance,
erived from pooled human
lasma, were 4.7% and 6.7% for
ol-CXCL16, 8.0% and 8.3% for
RP, 4.6% and 4.3% for resistin,
.66% and 20.4% for TNF-alpha,
nd 8.3% and 14.8% for sol-
CAM-1, respectively.
odent studies. At 8 weeks of age,
DL receptor null (LDL-R/)
ice on C57BL/6 background
Jackson Laboratories, Bar Har-
or, Maine) were fed rosiglita-
one (30 mg/kg/day in 0.25% w:v methylcellulose) or
ehicle for 7 days and injected intraperitoneally with LPS
200 ng/g), and blood was drawn for analysis of sol-
XCL16. Animal care procedures were approved by the
nstitutional Animal Care and Use Committee of the
niversity of Pennsylvania.
uman endotoxemia study. Healthy volunteers (3 men, 3
omen) ages 18 to 40 years were studied as described
reviously (16). Serial blood samples were collected for 24 h
efore and after the intravenous administration of human
esearch grade endotoxin 3 ng/kg (NIH Clinical Center,
CRE; lots 1 and 2; NIHCC PDS #67801). For this and
ther human studies, the Penn Institutional Review Board
pproved each study and written informed consent was
rovided by participants.
linical trial of pioglitazone. As described (17), 56 par-
icipants were recruited to a placebo-controlled trial of
ioglitazone (30 mg for 6 weeks and then 45 mg for 6
eeks) effects on atherogenic biomarkers in non-diabetic,
etabolic syndrome individuals.
ssociation study of plasma CXCL16 with coronary
therosclerosis. As described (18), 3,850 consecutive pa-
ients undergoing coronary angiography at Penn were re-
ruited to an Institutional Review Board-approved protocol
f risk factors for CVD. A 3-arm nested case-control
ample was randomly selected: 1) control patients with no
ngiographic CAD (n  235), 2) chronic CAD cases (2
essels 70% stenosis; n  268), and 3) ACS cases (n 
96), defined as CAD (any vessel 20% stenosis) in the
etting of myocardial infarction or unstable angina (chest
ain or dyspnea with elevated cardiac enzymes or dynamic
lectrocardiogram changes) within 48 h of angiography.
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CAD  coronary artery
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
ELISA  enzyme-linked
immunosorbent assay
HDL  high-density
lipoprotein
IFN  interferon
LPS  lipopolysaccharide
ox-LDL  oxidized low-
density lipoprotein
RNA  ribonucleic acid
TG  triglycerides
TNF  tumor necrosis
factorxclusions included ACS, cardiomyopathy, previous CAD,
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CXCL16 in Inflammation and Atherosclerosis January 30, 2007:442–9oronary angioplasty or coronary stent (for control patients),
ardiac transplant, or evaluation for vascular surgery or
rgan transplantation.
The metabolic syndrome was defined using a modified
body mass index 29 kg/m2 in men and 25 in women
19) version of the updated National Cholesterol Education
rogram definition (20). Fasting blood samples, drawn into
thylenediaminetetraacetic acid tubes before (1 h) angiog-
aphy, were kept at 4°C until same-day processing for
lasma, which was stored at 80°C. For this study, plasma
ol-CXCL16 levels were measured in plasma aliquots that
ad undergone 1 or 2 freeze-thaw cycles. Total and high-
ensity lipoprotein cholesterol (HDL-C), triglycerides
TG), and glucose levels were measured enzymatically on a
obas Fara II (Roche Diagnostic Systems Inc., New Jersey).
e calculated LDL-cholesterol using the Friedewald for-
ula except when TG levels were 400 mg/dl.
tatistical analysis. Data are reported as mean  SEM or
edian and interquartile range (25th, 75th percentile) and
s proportions for categorical variables. For experiments
ith multiple treatments, analysis of variance (ANOVA)
as used to test for differences in means; when significant
ifferences were found, post hoc Scheffe corrected t tests
ere used for comparisons. The effects of rosiglitazone (in
ice), pioglitazone (in humans), and human endotoxemia
n CXCL16 were tested by repeated-measures ANOVA.
The primary hypothesis tested in the case-control study
as that sol-CXCL16 was associated with both chronic
AD and ACS beyond established CVD risk factors and
RP compared with control patients. We present Spear-
an correlations with other continuous variables and a
ultivariable linear regression model (log-transformed sol-
XCL16 as outcome) examining which factors were inde-
endently associated with sol-CXCL16. Unadjusted asso-
iations with case-control status were examined using
NOVA. Logistic regression models were fit to test for
ssociation of quartiles (because of non-linear associations)
f sol-CXCL16 and CRP levels with chronic CAD and
CS. Models were adjusted for: 1) age, gender, and race; 2)
stablished risk factors (total cholesterol, HDL-C, triglyc-
rides, smoking, history of hypertension and diabetes, fam-
ly history of CAD, body mass index), and medications
beta-blocker, lipid therapy, aspirin, heparin within the
revious 24 h, angiotensin-converting enzyme inhibitors),
s well as age, gender, and race; and 3) CRP levels,
stablished risk factors, age, gender, and race. Gender and
ace interactions were assessed by likelihood-ratio test.
tatistical analyses were performed using Stata 9.0 software
Stata Corp., College Station, Texas).
esults
nduction of CXCL16 by LPS in vivo and attenuation by
nti-inflammatory drugs that target nuclear factor (NF)-
appa-B. Levels of whole-blood CXCL16 messenger
ibonucleic acid (mRNA) (Fig. 1A) and circulating sol-XCL16 (Fig. 1B) increased following an initial early
ytokine induction (TNF-alpha) during experimental
ndotoxemia. Thus, this extends to humans evidence in
itro that cytokines induce CXCL16 expression in hu-
an macrophages.
In vitro, aspirin blocked LPS induction of CXCL16
RNA (Fig. 2A) and protein (Fig. 2B) in human macro-
hages at concentrations (5 mM) that inhibit I-kappa-B
inase (21). Given this, we blocked this pathway using
N50, a cell-permeable peptide that prevents the translo-
ation of NF-kappa-B to the nucleus (22). SN50 signif-
cantly reduced the induction of sol-CXCL16 by LPS
Fig. 2C). In contrast, constitutive activation of NF-
appa-B, by overexpression of activated I-kappa-B ki-
ase, induced secretion of sol-CXCL16 to an extent
imilar to LPS (Fig. 2D).
XCL16 is down-regulated by peroxisome proliferator-
ctivated receptor (PPAR)-gamma activation in vitro
nd in vivo. Rosiglitazone, a thiazolidinedione (TZD)
PAR-gamma agonist with anti-inflammatory and anti-
Figure 1 Human Endotoxemia Induces CXCL16 In Vivo
(A) Whole-blood CXCL16 and tumor necrosis factor (TNF)-alpha messenger
ribonucleic acid (mRNA) and (B) plasma protein levels were measured serially
for 20 h before and 24 h after intravenous lipopolysaccharide (LPS) (3 ng/kg)
in 6 healthy volunteers. Repeated-measures ANOVA revealed significant effects
on CXCL16 mRNA (F  6.89, p  0.001) and sol-CXCL16 (F  6.15, p 
0.001) levels.
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January 30, 2007:442–9 CXCL16 in Inflammation and Atherosclerosistherosclerotic effects in mice (23) and humans (24), is
nown to attenuate inflammation, in part, by inhibition of
F-kappa-B (25). Pretreatment with rosiglitazone re-
uced LPS-induction of CXCL16 protein in macro-
hages (Fig. 3A). Rosiglitazone (30 mg/kg orally for 7
ays) reduced by 50% LPS-induced sol-CXCL16 levels
n LDL-R/ mice (Fig. 3B). Further, sol-CXCL-16
evels (ng/ml) were modestly but significantly reduced by
2-weeks of pioglitazone (from 2.29 [range 1.68 to 2.60]
o 2.13 [range 1.66 to 2.60]; n  28, p  0.03) but not
lacebo (from 2.22 [range 1.74 to 2.70] to 2.22 [range
.71 to 2.64]; n  28, p  0.82; between-group p 
.05) in metabolic syndrome subjects (17).
ssociation of sol-CXCL16 levels with CVD risk factors
nd atherosclerosis in humans. Before undertaking asso-
iation studies of CXCL16, we established the stability and
Figure 2 Inhibition of CXCL16 Induction by Anti-Inflammatory D
Down-regulation of (A) CXCL16 mRNA (F  19.4, p  0.001) and (B) CXCL16 pro
were pre-treated with aspirin for 2 h and then for 24 h with LPS (1 g/ml). **p 
regulation of CXCL16 mRNA in human macrophages by the nuclear factor-kappa-B
at 100 g/ml for 2 h, then for 24 h with LPS (1 g/ml). (D) Induction of CXCL16
kinase compared to control virus (*t test p  0.03). Results of representative exp
rescent protein; other abbreviations as in Figure 1.eproducibility of sol-CXCL16 in human plasma. Plasma bevels did not vary in 6 healthy subjects at multiple time
oints over the 24 h before (median pairwise r2  0.89).
XCL16 levels were remarkably stable in paired samples
tored at 80°C over a 3-month period in the 28 subjects
n the placebo arm of the pioglitazone trial (r2  0.89,
edian [interquartile range] coefficient of variance 
.25% [range 6.3% to 9.4%]). Sol-CXCL16 levels (me-
ian [interquartile range] ng/ml) were 2.50 (range 2.24 to
.07) after 1 freeze-thaw and 2.51 (range 2.21 to 2.84)
fter a second freeze-thaw in paired analysis of 35 plasma
amples.
The characteristics of the PENN-CATH case-control
tudy sample are summarized in Table 1. Briefly, 85% of
he sample was Caucasian, 55% was male, and the average
ge was 62 years. As expected, several established risk
actors, including family history, cigarette smoking, dia-
cretion (F  71.9, p  0.001) by aspirin (ASA) in human macrophages. Cells
***p  0.001 by t test compared to LPS-induced CXCL16 levels. (C) Down-
or SN50 (t test p  0.002). Cells were pretreated with SN50 or control peptide
an macrophages by adenovirus over-expression (24 h) of activated I-kappa-B
ts with triplicate samples are expressed as mean  (SEM). GFP  green fluo-rugs
tein se
0.01,
inhibit
in hum
erimenetes, metabolic syndrome, prior myocardial infarction,
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CXCL16 in Inflammation and Atherosclerosis January 30, 2007:442–9nd HDL-C and TG levels, as well as use of cardiac
edications, were higher in cases compared with control
atients; smoking and a history of myocardial infarction
ere more prevalent in ACS than chronic CAD cases.
lasma levels of both CRP and sol-CXCL16 were higher
n women than men within each case-control category.
ssociation of sol-CXCL16 levels with CVD risk factors.
e found significant associations of plasma sol-CXCL16
evels with inflammatory and metabolic factors (Table 2). In
articular, sol-CXCL16 was correlated with levels of CRP,
ol-ICAM1, and resistin, an inflammatory adipokine (16),
s well as higher TG and lower HDL-C. Levels (median
interquartile range], ng/ml) were modestly but significantly
reater in patients with the metabolic syndrome compared
o those without (2.65 [range 2.27 to 3.20] vs. 2.45 [range
.08 to 2.93], p  0.001). Notably, within any case-control
roup, levels of sol-CXCL16 did not differ significantly
etween statin users and non-statin users (e.g., in ACS
ases, 2.80 [range 2.40 to 3.31] vs. 2.77 [range 2.39 to
Figure 3 Inhibition of Sol-CXCL16 by
Rosiglitazone In Vitro and In Vivo
(A) Down-regulation of sol-CXCL16 protein by rosiglitazone (Rosi) in mouse
macrophages (*F  38.4, p  0.005; p  0.01 rosiglitazone/LPS versus
LPS alone). Cells were pretreated with rosiglitazone (1 M  24 h) and
then with LPS (1 g/ml  24 h). (B) LPS-dependent induction of plasma
sol-CXCL16 is blocked by rosiglitazone in mice (F  8.83, p  0.01).
LDLR/ mice (8 per group) were treated for 7 days with rosiglitazone (30
mg/kg) or vehicle and injected intraperitoneally with LPS (200 ng/g). Abbre-
viations as in Figure 1..22], p  0.75). In multivariable linear regression, temale gender (p  0.001), increasing age (p  0.001),
frican-American race (p  0.005), cigarette smoking
p  0.005), increasing TG (p  0.01), and lower
DL-C (p  0.05), as well as levels of resistin (p 
.001) and CRP (p  0.05), were independently associ-
ted with sol-CXCL16, even after adjusting for medica-
ions and case-control status.
ssociation of sol-CXCL16 with coronary atherosclerosis.
he association of sol-CXCL16 levels with CAD case-
ontrol status was similar across gender and race (all
nteractions p  0.4); therefore, results are combined for
en and women. Compared with control patients, sol-
XCL16 levels (Table 1) were higher (F  21.54; p 
.001) in patients with chronic CAD (p  0.01 vs. control
atients) and ACS (p  0.001 vs. control patients; p 
.001 vs. chronic CAD). In logistic regression, quartiles of
ol-CXCL16 levels were positively and incrementally asso-
iated with ACS compared with control patients follow-
ng adjustment for age, gender, race, medications, and all
raditional CVD risk factors, and even with further
djustment for plasma CRP levels (Table 3), levels above
he median were strongly associated with ACS in fully
djusted models that included medications and CRP data
odds ratio 2.52 [range 1.32 to 4.82]; p  0.005). The
ssociation of sol-CXCL16 quartiles with chronic CAD
as attenuated after adjusting for CVD risk factors
Table 3); however, levels above the median were statis-
ically significant predictors of chronic CAD in fully
djusted models (odds ratio 1.61 [range 1.01 to 2.58];
 0.04).
iscussion
XCL16 is remarkable among scavenger receptors because
t combines scavenger receptor and inflammatory chemo-
ine functions (4). Preliminary studies in humans have
rovided conflicting evidence for a role in atherosclerosis
10,15). We found that atherogenic inflammatory signals
nduce CXCL16 in human macrophages in vitro and in vivo
nd therapies that attenuate NF-kappa-B signaling inhibit
XCL16 induction. In humans, sol-CXCL16 levels were
odestly but positively associated with metabolic dyslipide-
ia and inflammatory risk factors. Consistent with this
ro-inflammatory profile, sol-CXCL16 levels were inde-
endently associated with coronary atherosclerosis, particu-
arly ACS.
Human endotoxemia is an established model of innate
mmunity activation that may provide mechanistic insight
nto the role of specific inflammatory pathways in human
isease. Lipopolysaccharide binds CD14, which delivers it
o its signaling receptor, toll-like receptor 4, leading to
ranslocation of NF-kappa-B to the nucleus driving gene
ranscription (26). Here we demonstrate that CXCL16 is
nduced during human endotoxemia and that activation of
F-kappa-B is necessary and sufficient for CXCL16 induc-
ion in human macrophages. We found that aspirin, at doses
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January 30, 2007:442–9 CXCL16 in Inflammation and Atherosclerosishat attenuate NF-kappa-B signaling (21), potently inhib-
ted CXCL16 induction, whereas atheroprotective TZDs
23,24), which antagonize NF-kappa-B via activation of
PAR-gamma, also down-regulate CXCL16 in mice and
umans. These data provide evidence that CXCL16 is
ctivated by inflammatory signals that promote atheroscle-
otic CVD.
A role for CXCL16 in atherosclerosis was first sug-
ested by findings of its accumulation in atherosclerotic
laques (6,14), its implication in foam cell formation as a
cavenger receptor (14), and a genetic study that associ-
ted a CXCL16 polymorphism with CAD (15). Sol-
XCL16 has several inflammatory functions and serves
s a T-cell activator (4,5,8,27), one of the first immune
ells found in developing atherosclerotic lesions (1).
-cells co-localize with CXCL16-expressing endothelial
Characteristics of the Case-Control Study Samp
Table 1 Characteristics of the Case-Control
Control Cases
(n  235)
Age (yrs) 61 11
Men (%) 46.4%
Race (%)
Caucasian 78.7%
African American 18.7%
Other 2.6%
History (%)
Family history of CAD 33.6%
Hypertension 57.5%
Current smokers 24.7%
Diabetes 16.6%
Prior myocardial infarction 6.0%
Body mass index (kg/m2) 29.9 7.0
Metabolic syndrome 43.8%
Laboratory profile
Total cholesterol (mg/dl) 177 36
LDL cholesterol (mg/dl) 107 31
HDL cholesterol (mg/dl)
Men 42 12
Women 52 15
Triglycerides (mg/dl) 94 (67–133)
C-reactive protein (mg/dl)
Men 1.74 (0.77–3.76
Women 2.94 (1.06–4.46
CXCL16 (ng/ml)
Men 2.19 (1.95–2.54
Women 2.45 (2.11–2.95
Medical treatment (%)
Statin 25.2
Aspirin 50.0
Beta-blocker 35.8
ACE-I or ARB 29.1
Insulin or oral hypoglycemic 12.6
Intravenous heparin 10.0
Data presented as percentages for categorical data and as mean SD
controls; †p  0.001 for ACS cases versus CAD cases; ‡p  0.01 ver
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angioten
lipoprotein; LDL  low-density lipoprotein.ells in plaques (27), and CXCR6, the only receptor for tXCL16, is highly expressed in immune and vascular
ells (4,5,28,29). Indeed, interferon (IFN)-gamma is a
trong inducer of CXCL16 expression (14) whereas
XCL16 is a stimulator of T-cell IFN-gamma produc-
ion (27), suggesting that CXCL16 may regulate athero-
enic effects of T-cells and IFN-gamma (1).
Surprisingly, Aslanian and Charo (11) reported recently
hat CXCL16 gene deficiency in LDL-R/ mice was
ssociated with accelerated atherosclerosis, despite a reduced
apacity of macrophages to accumulate oxidized LDL. This
tudy should be considered in the context of conflicting
eports for the role in mouse atherosclerosis of better
haracterized scavenger receptors SR-A and CD36. Despite
ost mouse studies supporting atherogenic effects of SR-A
nd CD36 (Suzuki, Sakguchi, Febbraio), recent work in
poE-deficient mice suggest no effect or even atheroprotec-
y Sample
Chronic Cases
(n  268)
Acute Cases
(n  196)
63 11 62 10
52.6% 69.9%*
88.1%† 88.8%*
11.6% 7.6%
0.3% 3.6%
45.2%* 45.4%*
72.0% 64.8%
37.7%* 71.0%*†
32.1%* 31.1%*
32.1%* 71.0%†
29.9 5.8 29.1 6.0
62.6%* 53.9%*
177 46 175 36
105 38 104 33
39 19* 41 10
46 12.0* 45 13*
117 (79–171)† 124 (93–169)*
2.23 (1.00–4.06) 4.14 (2.34–6.91)*
2.88 (1.42–4.88) 5.18 (3.13–7.78)*
2.5 (2.07–2.9)* 2.70 (2.32–3.01)*
2.69 (2.28–3.21)* 3.20 (2.74–3.68)*
52.6* 45.3*
76.5* 86.7*
64.5* 62.7*
40.6‡ 35.6‡
25.6‡ 20.0‡
16.4 63.0†
dian (interquartile range) for continuous variables. *p 0.001 versus
trol patient.
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therosclerosis.
Mouse models of atherosclerosis may provide only lim-
ted insight into the inflammatory pathophysiology of com-
lex atherosclerotic outcomes in humans. Despite this, the
ossibility that CXCL16 might be atheroprotective in
umans needs to be considered. Although we found that
lasma levels of sol-CXCL16 were positively related to
oronary atherosclerosis, these data conflict with a recent
eport by Sheikine et al. (10) suggesting that patients with
AD had reduced levels of sol-CXCL16. In their study,
owever, only a small number of patients (n  17) were
xamined at the time of presentation with ACS. Both
tudies used the same ELISA, and sol-CXCL16 levels were
imilar in both control populations. Our study had a much
arger sample of ACS cases, in which we observed the
trongest association with sol-CXCL16. We suggest that
ndings of negative regulation by anti-inflammatory thera-
ies, correlation with metabolic and inflammatory CVD risk
actors, and strong positive association with ACS in an
pearman Correlations of Sol-CXCL16evels With Cardiovascular Risk Factors
Table 2 Spearman Correlations of Sol-CXCL16Levels With Cardiovascular Risk Factors
Variable
Men
(n  387)
Women
(n  312)
All
(n  699)
Age 0.09 0.16* 0.15†
Systolic BP 0.06 0.04 0.04
Plasma glucose 0.03 0.05 0.06
Body mass index 0.02 0.09 0.06
LDL cholesterol 0.05 0.07 0.04
HDL cholesterol 0.07 0.21† 0.09‡
Triglycerides 0.08 0.21† 0.13†
CRP 0.26† 0.27† 0.28†
Soluble ICAM-1 0.15* 0.18* 0.16†
Resistin 0.15* 0.31† 0.23†
p  0.01; †p  0.001; ‡p  0.05.
BP blood pressure; CRP high-sensitivity C-reactive protein; HDL high-density lipoprotein;
CAM  intercellular adhesion molecule; LDL  low-density lipoprotein.
ultivariable Association of Plasma Sol-CXCL16 and CRP Quartiles
Table 3 Multivariable Association of Plasma Sol-CXCL16 and C
Model 1
Chronic CAD
Cases ACS Cases
Chronic C
Cases
CRP
Q2 1.54 (0.97–2.47) 3.11 (1.55–6.82) 1.54 (0.86–
Q3 0.99 (0.61–1.61) 5.13 (2.60–10.09) 0.62 (0.33–
Q4 1.85 (1.07–3.22) 16.44 (8.15–33.17) 1.58 (0.77–
CXCL16
Q2 1.26 (0.78–2.04) 3.62 (1.90–6.92) 1.42 (0.81–
Q3 2.71 (1.59–4.60) 9.76 (4.91–19.38) 2.01 (1.08–
Q4 2.75 (1.60–4.73) 14.10 (6.90–28.80) 1.81 (0.93–
esults are presented as odds ratio (95% confidence interval) of CAD status comparing incrementa
nd race; Model 2 adjusted for age, gender, race, and risk factors (total cholesterol, HDL cholestero
ass index, and medications [beta-blocker, lipid lowering therapy, aspirin, heparin, angiotensin-c
odeling sol-CXCL16) or sol-CXCL16 data (when modeling CRP) as well as age, gender, race, and
.02 to 8.29 ng/ml for sol-CXCL16 and 0.01 to1.35, 1.35 to3.01, 3.01 to4.87, and 4.87 to
ith ACS or chronic CAD cases.
ACS  acute coronary syndrome; CAD  coronary artery disease, other abbreviations as in Table 2.ppropriately sized sample provide indirect support for a
ro-inflammatory role for CXCL16 in human CVD.
verall, conflicting findings underscore the need for
dditional clinical studies and experiments using diverse
nimal models.
The concept that several circulating inflammatory
arkers may provide prognostic value is consistent with
he complex pathophysiology of atherosclerosis and its
iverse manifestations (1). In this context, we found that
ol-CXCL16 levels were strong independent predictors
f ACS as well as independent of and superior to CRP in
ssociation with chronic CAD. Plasma levels were re-
arkably stable under basal conditions, suggesting that
ol-CXCL16 may have favorable biomarker characteris-
ics for epidemiologic and clinical application. Overall,
ur findings require replication in prospective,
opulation-based studies of diverse CVD end points that
lso compare the diagnostic and prognostic value of
ol-CXCL16 to additional biomarkers.
In conclusion, we found that inflammatory signals that
romote atherosclerosis also induce CXCL16 in vitro and
n vivo. Consistent with this pro-inflammatory induction,
ol-CXCL16 levels were positively associated with coro-
ary atherosclerosis. Despite conflicting reports, our
tudies provide support for CXCL16 as a pro-
nflammatory factor in human atherosclerosis, especially
cute coronary syndromes.
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2.85 (1.07–7.56) 1.44 (0.79–2.60) 2.49 (0.89–7.01)
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